Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center.
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.
J Atheroscler Thromb. 2023 May 1;30(5):467-480. doi: 10.5551/jat.63554. Epub 2022 Jul 6.
Genetic and medical insights from studies on cardioprotective phenotypes aid the development of novel therapeutics. This study identified genetic variants associated with supernormal coronary arteries using genome-wide association study data and the corresponding genes based on expression quantitative trait loci (eQTL).
Study participants were selected from two Korean cohorts according to inclusion criteria that included males with high cardiovascular risk (Framingham risk score ≥ 14, 10-year risk ≥ 16%) but with normal coronary arteries (supernormal group) or coronary artery disease (control group). After screening 12,309 individuals, males meeting the supernormal phenotype (n=72) and age-matched controls (n=94) were enrolled. Genetic variants associated with the supernormal phenotype were identified using Firth's logistic regression, and eQTL was used to evaluate whether the identified variants influence the expression of particular genes in human tissues.
Approximately 5 million autosomal variants were tested for association with the supernormal phenotype, and 10 independent loci suggestive of supernormal coronary arteries (p<5.0×10) were identified. The lead variants were seven intergenic single-nucleotide polymorphisms (SNPs), including one near PBX1, and three intronic SNPs, including one in PPFIA4. Of these variants or their proxies, rs9630089, rs6427989, and rs4984694 were associated with expression levels of SLIT1 and ARHGAP19, PPFIA4, and METTL26 in human tissues, respectively. These eQTL results supported their potential biological relevance.
This study identified genetic variants and eQTL genes associated with supernormal coronary arteries. These results suggest candidate genes representing potential therapeutic targets for coronary artery disease.
对具有心脏保护表型的基因和医学研究提供了遗传学见解,有助于开发新型治疗方法。本研究使用全基因组关联研究数据和基于表达数量性状基因座 (eQTL) 的相应基因,鉴定与超常冠状动脉相关的遗传变异。
根据纳入标准,从两个韩国队列中选择研究参与者,纳入标准包括心血管风险高(Framingham 风险评分≥14,10 年风险≥16%)但冠状动脉正常(超常组)或冠状动脉疾病(对照组)的男性。在筛选了 12309 个人之后,纳入了符合超常表型的男性(n=72)和年龄匹配的对照者(n=94)。使用 Firth 的逻辑回归鉴定与超常表型相关的遗传变异,并使用 eQTL 评估鉴定的变异是否影响人类组织中特定基因的表达。
大约 500 万个常染色体变异用于与超常表型相关的关联分析,鉴定出 10 个提示与超常冠状动脉相关的独立位点(p<5.0×10)。主要变异是七个基因间单核苷酸多态性(SNP),包括 PBX1 附近的一个,以及三个内含子 SNP,包括 PPFIA4 中的一个。这些变体或其近缘变体中,rs9630089、rs6427989 和 rs4984694 与人类组织中 SLIT1 和 ARHGAP19、PPFIA4 和 METTL26 的表达水平相关。这些 eQTL 结果支持了它们潜在的生物学相关性。
本研究鉴定了与超常冠状动脉相关的遗传变异和 eQTL 基因。这些结果表明候选基因可能是冠状动脉疾病的潜在治疗靶点。